GeoVax Sponsors 2025 Global Health Equity Summit, Emphasizing Vaccine Access for Underserved Populations

GeoVax, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit hosted by Morehouse School of Medicine. The summit, taking place October 2, 2025, in Atlanta, Georgia, convenes global health experts, policymakers, researchers, community organizations, and students to address pressing challenges in health equity under the theme "The Quest for Health Equity & Justice: A Glocal Perspective."

The sponsorship underscores GeoVax's strategic focus on ensuring that scientific innovations in vaccine development translate into real-world accessibility for underserved populations. This commitment comes at a critical time when global health disparities continue to widen, particularly in vaccine access for immunocompromised individuals and marginalized communities. The company's participation signals a growing recognition within the biotechnology industry that equitable distribution of medical advancements is essential for meaningful public health impact.

Representing GeoVax at the summit will be Mary Hauser, PhD, Director of Preclinical Research, who will highlight the company's work advancing MVA-based vaccines designed specifically to meet the needs of immunocompromised and underserved populations. This technology platform represents a significant advancement in vaccine development, particularly for patients who may not respond adequately to conventional vaccines. The summit will feature keynote speaker Dr. John N. Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, alongside distinguished leaders across academic, government, and private sectors.

David Dodd, Chairman & CEO of GeoVax, emphasized the company's perspective that "Health equity is not just a goal - it is a mandate for global progress." This statement reflects the growing consensus among healthcare leaders that equitable access to medical innovations is fundamental to achieving sustainable development goals and improving global health outcomes. The sponsorship aligns with GeoVax's clinical development strategy, particularly its lead COVID-19 vaccine candidate GEO-CM04S1, which is being evaluated as a primary vaccine for immunocompromised patients in three Phase 2 clinical trials.

The implications of GeoVax's involvement extend beyond corporate sponsorship, representing a tangible commitment to addressing systemic barriers in healthcare access. Sessions at the summit will explore critical topics including vaccine access and trust, innovations in pandemic preparedness, and community-driven models for health equity - all areas where GeoVax's technology platform could make significant contributions. The company's anticipation of progressing directly to Phase 3 clinical evaluation for its Mpox and smallpox vaccine, based on recent EMA regulatory guidance, further demonstrates the potential for accelerated development pathways that could benefit populations most affected by health disparities.

For stakeholders in global health, biotechnology, and public policy, GeoVax's sponsorship represents an important convergence of scientific innovation and social responsibility. The company's focus on developing vaccines for populations poorly served by current authorized COVID-19 vaccines addresses a critical gap in pandemic response capabilities. More information about GeoVax's clinical trials and technology platform is available at https://www.geovax.com. The Dr. David Satcher Global Health Equity Summit, founded in honor of the 16th Surgeon General of the United States, continues to serve as a catalyst for collaboration and action toward sustainable change in global and community health, with GeoVax's participation highlighting the essential role of private sector engagement in achieving health equity objectives.